Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4759976
Max Phase: Preclinical
Molecular Formula: C25H34N4O5
Molecular Weight: 470.57
Molecule Type: Unknown
Associated Items:
ID: ALA4759976
Max Phase: Preclinical
Molecular Formula: C25H34N4O5
Molecular Weight: 470.57
Molecule Type: Unknown
Associated Items:
Canonical SMILES: COCC(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)(C)C)NC(=O)c1cc2ccccc2[nH]1
Standard InChI: InChI=1S/C25H34N4O5/c1-25(2,3)13-20(29-23(32)19-11-15-7-5-6-8-17(15)27-19)24(33)28-18(21(30)14-34-4)12-16-9-10-26-22(16)31/h5-8,11,16,18,20,27H,9-10,12-14H2,1-4H3,(H,26,31)(H,28,33)(H,29,32)/t16-,18-,20-/m0/s1
Standard InChI Key: IULLQBINVRGFGJ-QRFRQXIXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 470.57 | Molecular Weight (Monoisotopic): 470.2529 | AlogP: 1.93 | #Rotatable Bonds: 10 |
Polar Surface Area: 129.39 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.74 | CX Basic pKa: | CX LogP: 1.42 | CX LogD: 1.42 |
Aromatic Rings: 2 | Heavy Atoms: 34 | QED Weighted: 0.42 | Np Likeness Score: -0.10 |
1. Hoffman RL,Kania RS,Brothers MA,Davies JF,Ferre RA,Gajiwala KS,He M,Hogan RJ,Kozminski K,Li LY,Lockner JW,Lou J,Marra MT,Mitchell LJ,Murray BW,Nieman JA,Noell S,Planken SP,Rowe T,Ryan K,Smith GJ,Solowiej JE,Steppan CM,Taggart B. (2020) Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19., 63 (21): [PMID:33054210] [10.1021/acs.jmedchem.0c01063] |
Source(1):